返回 
加入收藏
贝伐珠单抗在我院抗肿瘤治疗中的应用分析
x
请在关注微信后，向客服人员索取文件
| 篇名： | 贝伐珠单抗在我院抗肿瘤治疗中的应用分析 |
| TITLE： | |
| 摘要： | 目的：了解贝伐珠单抗在抗肿瘤治疗中的应用情况，以促进该药的临床合理使用。方法：回顾性收集2011年1月－2015年12月我院接受贝伐珠单抗治疗的265例肿瘤患者的病历资料，对患者的肿瘤类型、贝伐珠单抗的临床地位、治疗方案、用药次数、治疗周期进行统计和分析，计算主成分参数并进行主成分分析和聚类分析。结果：265例患者共涉及18类恶性肿瘤，以结直肠癌（48.68％）、卵巢癌（20.75％）、肺癌（9.43％）为主；贝伐珠单抗抗肿瘤治疗用于一线、二线、三线的比例分别为10.28％、26.39％、23.61％；其肿瘤治疗涉及肿瘤类型主要为结直肠癌、卵巢癌、肺癌；其抗肿瘤治疗的肿瘤类型可聚为4类，结直肠癌为一类，卵巢癌为一类，肺癌为一类，其他为一类。贝伐珠单抗与化疗药物联用方案有347例次（90.84％），贝伐珠单抗单用方案有35例次（9.16％）；在贝伐珠单抗与化疗药物联用方案中，以与含氟尿嘧啶等抗代谢类药物联用（50.54％）、与含紫杉类药物联用（18.05％）、与铂类药物联用（16.50％）为主。有1例患者最多使用了69次贝伐珠单抗，有44例患者各使用了1次；有1例次治疗了51个周期，有85例次治疗了1个周期，以治疗1～4个周期最为常见。结论：贝伐珠单抗作为首个上市的抗血管生成药物，在临床恶性肿瘤（实体瘤）的治疗中具有一定的地位，已成为结直肠癌、卵巢癌和肺癌的一线治疗药物，但由于其药理作用的局限性，该药与化疗药物的联用仍是主要方向。 |
| ABSTRACT： | OBJECTIVE： To investigate the application of bevacizumab in anti-tumor treatment， and to promote rational use of it in clinic. METHODS： The medical records of 265 cancer patients receiving bevacizumab were analyzed retrospectively in our hospital during Jan. 2011-Dec. 2015 in respects of tumor types of patients， clinical status of bevacizumab， treatment plan， frequency of medication and treatment cycle. Principal component analysis， and cluster analysis of were conducted on the basis of calculation of principle component parameter. RESULTS： Among 265 patients， 18 categories of malignant tumor were involved， being mainly colorectal malignant tumor （48.68％）， ovarian malignant tumor （20.75％） and lung malignant tumor （9.43％）. The proportion of first-line， second-line and third-line bevacizumab anti-tumor therapy were 10.28％， 26.39％， 23.61％， respectively. The tumor types of anti-tumor therapy were colorectal cancer， ovarian cancer and lung cancer. The types of tumor in anti-tumor therapy could be clustered into four categories； colorectal cancer was clustered into one category； ovarian cancer was clustered into one category； lung cancer was clustered into one category； other cancer type was clustered into one category. There were 347 cases of bevacizumab combined with chemotherapy drugs （90.84％） and 35 cases of bevacizumab alone （9.16％）. Among bevacizumab chemotherapy drug combination plan， bevacizumab mainly combined with antimetabolitas （50.54％）， drugs containing paclitaxel （18.05％） and platinum （16.50％）. A patient was given bevacizumab for 69 times at the most， while 44 patients were given bevacizumab for one time. One case was treated for 51 courses， while 85 cases were treated for one course. Most of them were treated for 1-4 courses. CONCLUSIONS： As the first listed anti-angiogenic drug， bevacizumab has a certain clinical status in the treatment of malignant tumors， and has become first-line treatment drug for colorectal cancer， ovarian cancer and lung cancer. Due to the limits of pharmacological effects， bevacizumab combined with chemotherapy plan is still the main direction. |
| 期刊： | 2018年第29卷第16期 |
| 作者： | 张轶雯，方罗，钟里科，郑烨娇，潘宗富，黄萍 |
| AUTHORS： | ZHANG Yiwen，FANG Luo，ZHONG Like，ZHENG Yejiao，PAN Zongfu，HUANG Ping |
| 关键字： | 贝伐珠单抗；抗肿瘤治疗；临床应用；分析 |
| KEYWORDS： | Bevacizumab； Tumor therapy； Clinical application； Analysis |
| 阅读数： | 270 次 |
| 本月下载数： | 11 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
